Cargando…
FRI428 VTE And Testosterone Therapy: What Is The Risk?
Disclosure: C. Cheatham: None. J. Colburn: None. M. Kemm: None. Testosterone replacement therapy (TRT) to treat hypogonadism from a variety of underlying etiologies remains increasingly prevalent within the United States. While VTE is a known potential risk, the prevalence, underlying mechanism, and...
Autores principales: | Cheatham, Callie, Colburn, Jeffrey, Kemm, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554063/ http://dx.doi.org/10.1210/jendso/bvad114.1619 |
Ejemplares similares
-
FRI431 Erythrocytosis Associated With Oral Testosterone Replacement
por: Engel, Ashley A, et al.
Publicado: (2023) -
FRI403 The Unintended Consequences Of Applying Topical Testosterone Directly To The Scrotum
por: Melendez-Rivera, Juan Gabriel, et al.
Publicado: (2023) -
ODP428 The Effects of Asprosin Pubertal Maturation in Female Rats
por: OZ, Zeynep Dila, et al.
Publicado: (2022) -
FRI434 Long-term Self-reported Outcomes Of Randomized Testosterone (T) vs Placebo (P) Treatment In The T4DM Study
por: Handelsman, David J, et al.
Publicado: (2023) -
FRI436 Design Of An International Male Contraceptive Efficacy Trial Using A Self-administered Daily Topical Gel Containing Testosterone And Nestorone™
por: Page, Stephanie T, et al.
Publicado: (2023)